Welcome to AZ MedX

AstraZeneca’s Respiratory & Immunology medical resource centre for healthcare professionals

Discover the latest advances and approaches in asthma, COPD and more

This site is intended for the use of Healthcare Professionals only. By clicking the link below you declare and confirm:

If you are not a Healthcare Professional, please follow this link for information on global patient resources.

International Severe Asthma Registry – ISAR

What is ISAR?

ISAR is a global, collaborative initiative to gather anonymous, longitudinal, real-life data for patients with severe asthma from over 29 countries (n=8514). ISAR offers a rich source of real-life data for scientific research to understand and improve symptoms, optimise treatments and patient outcomes for severe asthma. The database provides an international platform for research collaboration in respiratory medicine.

International collaborators include:

  • OPC logo

    Optimum Patient Global

    Co-sponsorship, project management and delivery

  • AstraZeneca logo



  • Respiratory Effectiveness Group logo

    Respiratory Effectiveness Group

    Academic partner

  • OPRI logo

    Observational Pragmatic Research Institute

    Country-specific registries

What are the ISAR goals?

The goals of ISAR are to:

  • Standardise and integrate data collection by using a core set of variables across all participating countries. Variables were selected using a modified Delphi process [1]
  • Support data collection – electronic data capture, hosting and data entry
  • Enable collaborating countries to answer key research questions in severe asthma on a global scale
  • Improve the care of severe asthma patients.


ISAR is governed by four independent bodies:

  • ISAR steering committee: Renowned researchers in the field of severe asthma from 21 countries and four AZ members
  • Respiratory Effectiveness Group (REG): Academic partner and international experts in severe asthma
  • ADEPT committee: Researchers into ethical oversight (operational for the past five years) and senior researchers with clinical, epidemiological and/or database expertise
  • Operational committee: Participating country representatives


If you would like more information about the ISAR registry, why not contact us or take a look at the ISAR website.

ISAR Progress


Total number of patients


Prospective patient-level data


Target for prospective patient recruitment by 2022 with severe asthma

Agreements executed

Agreements in progress

Collaborating independent registries

Status as at 21 July 2020

UK | n=714

Ireland | n=18

Spain | n=359

Portugal | n=70

Denmark | n=264

Italy | n=992

Bulgaria | n=227

Greece | n=63

Saudi Arabia | n=55

Kuwait | n=217

United Arab Emirates | n=40

Canada | n=128

Mexico | n=31

USA | n=115

Colombia | n=141

Argentina | n=51

India | n=71

Korea (Republic of) | n=68

Japan | n=99

Taiwan | n=53

Patients are eligible for inclusion, into the ISAR Registry, if they have asthma requiring GINA Step 5 treatment or GINA Step 4 treatment and uncontrolled asthma.

  • Click here to see the full list of participating countries

    Countries Lead
    Argentina Jorge Maspero
    Australia Peter G. Gibson
    Bulgaria George C. Christoff
    Canada J. Mark FitzGerald
    Colombia Carlos Torres
    Denmark Celeste M. Porsbjerg
    Estonia Alan Altraja
    Finland Lauri Lehtimäki
    France Arnaud Bourdin
      Camille Taille
    Germany Christian Taube
    Greece Andrianna I. Papaioannou
    Iceland Unnur Björnsdóttir
    India Sundeep Salvi
    Ireland Richard W. Costello
    Italy George Walter Canonica
    Enrico Heffler
    Japan Takashi Iwanaga
    Kuwait Mona Al-Ahmad
    Mexico Désirée Larenas Linnemann
    Norway Sverre Lehmann
    Poland Piotr Kuna
    Portugal João A Fonseca
    Saudi Arabia Riyard Al-Lehebi
    Singapore Mariko Koh Siyue
    South Korea Chin Kook Rhee
    Spain Luis Perez-de-Llano
    Sweden Leif Bjermer
    Taiwan Steve Perng Diahn-Warng
    United Arab Emirates Bassam Mahboub
    United Kingdom Andrew Menzies-Gow
    Liam G. Heaney
    United States of America Eileen Wang
  • Click here to learn more about ISAR research projects

    Priority research topics by ISAR for 2020 are:

    The impact of comorbidity in severe asthma

    Defining responders and non-responders to biologics and describing their characteristics overall and per biologic

    Describing the clinical outcome before and after biologic treatment by biologic class, by individual biologic and by subgroups of baseline characteristics.

    To see the full list of research projects, please visit the ISAR website

You are now leaving: http://azmedx.com/

By following this link you will be leaving the AZ MedX website.

Please note that AstraZeneca does not take responsibility for the content displayed on other websites.

Continue Return to AZ MedX